Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: Wally Mastroly who wrote (204)	5/4/1998 2:18:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 399

ARQL initiates bone disease program biz.yahoo.com This is very interesting. This is a new twist on the business model. ARQL will retain a right to obtain exclusive rights to any drug candidates identified. In addition, the collaboration is with an academic institution and not another biotech. I took a look at the research underlying this and it is quite impressive. They are working on the structure of the parathyroid hormone receptor on bone. This is a G-protein-coupled receptor. They have made good progress on understanding the active region of the receptor and its conformation and have investigated the ability of various molecules to stimulate the receptor. They appear to use a fluorescence based assay of PTH receptors expressed in HEK C21 cells. This is an excellent point to bring in ARQL's chemistry. When you have a pretty good idea what kind of molecule your looking for, ARQL's mapping and directed array are perfect for developing and optimizing candidate molecules. In addition, the existence of a sensitive, fluorescence based, cellular assay should allow for high throughput screening in a biologically meaningful system. All in all, this looks to be another in a long line of exceptional collaborations for ARQL. The long term potential of this company keeps growing and growing and growing. I just keep wondering when the market is going to catch on. John de C